'Imported drugs' | get together into China | 2018 or will be on the market of innovative drugs on the New Year

According to incomplete statistics, about 20 innovative pharmaceuticals approved by foreign-funded enterprises in China are approved for listing in China in 2017, of which about 35% are oncology drugs.Experts believe that by 2018 or another cancer-initiating drug Listed on the New Year.At present, more than 10 companies have announced the approval of new drugs will be listed in 2018, most of the innovative drugs.From the declaration of new drugs situation, the domestic innovative drugs are in the early stages of development, the approved species is relatively small , But the number of declaring varieties is gradually increasing.

According to incomplete statistics, about 20 innovative pharmaceuticals approved by foreign-funded enterprises in China will be approved for listing in China in 2017, of which about 35% will be oncology drugs, as the 'priority review' system officially falls into place in the country. Experts believe that in 2018 or will be another year of listing of innovative drugs oncology.

China Network Financial reporters combed that at present there are already more than 10 companies announced that 2018 will be approved for listing of new drugs, most of the innovative drugs for cancer.

February 26, 2016, the State Food and Drug Administration released the "General Administration on the solution drug Prior to the State Food and Drug Administration (CFDA) statistics show that in the period from 2001 to 2016, the development of the "advanced review and approval of opinions" announcement, marking the formal evaluation of the 'priority review' system in the country before the official statistics There are 433 kinds of innovative drugs listed in the country, with over 100 kinds being listed in China, which lags behind the listing of new foreign drugs in China mainly due to China's drug trial system.

After reviewing the implementation of the New Deal, about 20 new foreign pharmaceutical companies have been approved for domestic listing in 2017, including multinationals such as Bayer, Novartis, Sanofi, Johnson & Johnson and AstraZeneca, which include hepatitis C, Diabetes, Parkinson's disease, AIDS, hypertension , Depression, etc. According to incomplete statistics, about 35% of these new drugs are Tumor Drugs, about 20% for the treatment of hepatitis C drugs, 10% for the treatment of diabetes drugs.

medicine Writer Liu Qian analysis believes that with the tumor basic research breakthroughs, coupled with the market, strong willingness to pay and other reasons, is expected to 2018 is a cancer drug listing year .China.com financial reporters combed that there are already cutting-edge biology , Bristol-Myers Squibb, Hengrui, more than 10 pharmaceutical companies said their new drugs are expected to be approved in the domestic market in 2018. The treatment of these new drugs, including ovarian cancer, anemia, long-acting AIDS drugs, colorectal cancer, stomach cancer, etc. , Of which the highest proportion of tumor innovative drugs still accounted for.

Among the new drugs expected to be listed in 2018, innovative drugs from state-owned enterprises are also showing no sign of weakness and new drugs such as Frontier Biologicals, Hengrui Medicine, CTT Fine and Hehuang Pharmaceutical will be approved for approval. According to Liu Qian, a medical writer, Ching Tai Fine, Hutchison medicine three enterprise Although the mechanism of action and indications vary with the small molecule titanide marketed in 2018, all have applied for the indications of gastrointestinal tumors. "Since all three products belong to the Me-too new drug category, future products The key to business performance is the ability of the company to innovate in marketing.

On January 2, 2018, Livzon Group announced that the company's application for registration of Ipazole sodium for injection and the application for registration of Ippzazole sodium raw materials have all been changed to 'Approval finished - System Certificates', which means heavy-duty varieties of Ipolazole for injection are expected to be approved recently.

According to the data, in the early stage of the development of new drugs, the number of approved new drugs in the country is still at an early stage of development, with a relatively small number of approved products, however, the number of new domestic drugs newly declared in each year has reached more than 300 The types of these declarations are expected to be gradually approved after 3-5 years.